Related Experiment Video
Updated: Aug 9, 2026
05:16
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Circulating adiponectin concentrations in patients with congestive heart failure
1The Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. jacobg@post.tau.ac.il
Heart (British Cardiac Society)
|April 20, 2006
Summary
Adiponectin levels are elevated in congestive heart failure (CHF) patients. Higher adiponectin concentrations predict increased mortality and hospitalizations in CHF patients, highlighting its role in disease progression.
Area of Science:
- Cardiology
- Endocrinology
- Biomarkers
Background:
- Congestive heart failure (CHF) is a complex syndrome with various contributing factors.
- Adiponectin, an adipokine, plays a role in metabolic regulation and inflammation.
- Understanding novel biomarkers in CHF is crucial for improved patient outcomes.
Purpose of the Study:
- To measure adiponectin concentrations in patients with congestive heart failure (CHF).
- To assess the predictive value of adiponectin on clinical outcomes in CHF patients.
Main Methods:
- Serum samples and clinical data were collected from 175 outpatients with clinically controlled CHF.
- Concentrations of adiponectin and other inflammatory markers (CRP, NT-proBNP, ILs, TNF-α, CD40L) were measured.
- Statistical analyses were performed to determine associations and predictive values for mortality and hospitalizations.
Main Results:
- Adiponectin levels were significantly higher in CHF patients compared to controls.
- Elevated adiponectin correlated with higher New York Heart Association class.
- Adiponectin above the 75th percentile independently predicted mortality and CHF hospitalizations over two years.
Conclusions:
- Adiponectin is significantly elevated in patients with congestive heart failure.
- Serum adiponectin concentration serves as an independent predictor of adverse outcomes, including mortality and hospitalizations, in CHF patients.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...